AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
When asked about On CNBC's "Mad Money Lightning Round," Jim Cramer said AbbVie Inc. (NYSE:ABBV) is doing "very, very well." However, he added that Abbott Laboratories (NYSE:ABT) remains his favorite in the group right now.
在CNBC的"瘋狂金錢閃電輪"節目中，吉姆·克萊默表示，艾伯維公司（ABBV股票代碼：NYSE:ABBV）表現"非常非常好"。然而，他補充說，雅培公司（股票代碼：紐約證券交易所：ABT）目前仍是他最喜歡的公司。
AbbVie was founded in 2013 when it became a separate company from Abbott.
艾伯維公司成立於2013年，當時它從雅培公司中分拆形成了獨立公司。
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
在10月9日，瑞銀分析師納文·雅各布維持艾伯維公司的中立評級，並將目標股價從185美元上調至195美元。
When asked about Oracle (NYSE:ORCL), he said, "I like the prospects. But you're in it for the data center, and the data center business is excellent."
當被問及甲骨文公司（ORCL股票代碼：紐約證券交易所：ORCL）時，他表示:"我看好前景。但你是爲了數據中心，而數據中心業務表現卓越。"
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between healthcare providers and payers.
甲骨文公司最近推出了Oracle Health Clinical Data Exchange，這是一種基於雲的解決方案，通過安全、自動化的數據交換簡化醫療理賠處理，醫療服務提供商和付款方之間進行數據交換。
Core Scientific, Inc. (NASDAQ:CORZ) is a "mini-Palantir," Cramer said. He recommended buying Palantir (NYSE:PLTR).
Core Scientific, Inc.（NASDAQ:CORZ）是一家小型版"palantir"，克萊默表示。他建議買入Palantir（紐約證券交易所：PLTR）。
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
10月11日，萊利證券分析師盧卡斯·派普斯維持對Core Scientific公司的買入評級，並將目標股價從13美元上調至14美元。
"I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody," Cramer said when asked about Clover Health Investments, Corp. (NASDAQ:CLOV).
"我就是不想討論它。我知道這是一家好公司，但我就是不想傷害任何人，"克萊默在被問及Clover Health Investments, Corp.（NASDAQ:CLOV）時表示。
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
公司最近表示，康哲藥業（CMS）將其PPO醫療優勢計劃的星級評定提高到2025年的四星，影響到2026年的支付。
GXO Logistics (NYSE:GXO) is a "very valuable company," the "Mad Money" host said. "Just hold on."
GXO物流（紐交所：GXO）是一家"非常有價值的公司"，"瘋狂金錢" 主持人表示。"只要持有"。
GXO recently announced a new transport partnership with Matalan.
GXO最近宣佈與Matalan達成新的運輸合作伙伴關係。
Cramer said he really likes Sweetgreen, Inc. (NYSE:SG), adding that it is "terrific."
Cramer表示他非常喜歡Sweetgreen, Inc.（紐交所：SG），並補充說它是"了不起的"。
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Sweetgreen將於11月7日星期四收盤後發佈第三季度的財務業績。
Price Action:
價格行動：
- Oracle shares gained 0.4% to settle at $174.77 on Wednesday.
- AbbVie shares fell 0.7% to close at $190.46.
- Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.
- GXO Logistics shares gained 2.6% to settle at $62.95.
- Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.
- 甲骨文股價週三上漲0.4%，收於174.77美元。
- 艾伯維公司股價下跌0.7%，收於190.46美元。
- Core Scientific股價週三上漲2.2%，收盤價爲13.25美元。
- GXO物流股價上漲2.6%，收於62.95美元。
- Sweetgreen股價週三下跌0.7%，收盤價爲37.94美元。
- Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields
- 華爾街最準確的分析師對三隻消費股票的高股息收益率進行評估
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。
